Natera, INC

Natera, Inc. announced the appointment of Thomas Lynch to its Board of Directors and an amendment to a previous 8-K filing to include XBRL tagging.

Natera, Inc. announced the results of its Annual Meeting of Stockholders, including the approval of an amendment to its 2015 Equity Incentive Plan to reserve an additional 3.2 million shares.

Natera, Inc. has increased its board size to twelve members with the appointment of Dr. Thomas Lynch as an independent director.

Natera, Inc. announced the expansion of its Board of Directors to eleven members and the appointment of Eric Rubin as an independent Class I director.

Natera, Inc. announced robust financial results for Q4 and full-year 2025, driven by significant revenue growth, improved gross margins, and record test volumes.

Natera announced preliminary unaudited financial results for Q4 and full-year 2025, showing significant revenue and test volume growth driven by record Signatera expansion.

Natera, Inc. announced a significant increase in Q3 2025 revenues and improved gross margins, despite a substantial rise in net losses and ongoing legal challenges.

Natera, Inc. announced significant revenue increases for Q2 and H1 2025, driven by test volume growth, but reported a substantially wider net loss and faced major adverse legal judgments.

Natera, Inc. reports a 36.5% increase in total revenue for Q1 2025, driven by growth in product revenues from Panorama, Horizon, and Signatera tests.

Natera Inc. saw a significant increase in revenue during the third quarter of 2024, primarily driven by higher test volumes and improved average selling prices.

Natera Inc. saw a significant increase in revenue during the second quarter of 2024, driven by growth in product sales, and announced the redemption of its convertible senior notes.

Natera, Inc. saw a significant increase in revenue during the first quarter of 2024, primarily driven by higher test volumes and improved average selling prices.

Natera, Inc. reported significant revenue growth in 2025, driven by increased test volumes across its oncology, women's health, and organ health segments, alongside strategic acquisitions and facility expansions.

Natera reports significant revenue growth in 2024, driven by increased demand for its genetic testing products, while simultaneously reducing net losses.

Natera, Inc. saw a significant increase in revenue and a decrease in net losses in 2023, driven by growth in its core product offerings.

Jonathan Sheena, a Director of Natera, Inc., sold 479 shares of common stock on July 27, 2026.

Matthew Rabinowitz, EXECUTIVE CHAIRMAN and a Director of Natera, Inc., sold 1,718 shares of common stock on July 27, 2026 for $260.49 per share.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., sold 1,887 shares of common stock on July 27, 2026.

Solomon Moshkevich, PRESIDENT, CLINICALDIAGNOSTICS of Natera, Inc., sold 2,214 shares of common stock on July 27, 2026.

John Fesko, PRESIDENT, CHIEF BUS. OFFICER of Natera, Inc., sold 1,713 shares of common stock on July 27, 2026.

Steven Leonard Chapman, CEO AND PRESIDENT and a Director of Natera, Inc., sold 5,770 shares of common stock on July 27, 2026.

Natera, Inc. has released its 2026 proxy statement detailing director elections, executive compensation, and a proposed amendment to its 2015 Equity Incentive Plan.

Natera, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, to vote on director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.

Natera, Inc. has scheduled its 2025 Annual Meeting of Stockholders for June 12, 2025, to be held virtually, and has released its proxy statement outlining key proposals for stockholder consideration.

Natera, Inc. supplements its proxy statement to clarify amendments to its 2015 Equity Incentive Plan, explicitly prohibiting repricing or cash buyouts of underwater options and stock appreciation rights without stockholder approval.

Natera, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, with voting open until June 11, 2024.

Natera, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 12, 2024, to address director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.

Vanguard Capital Management has reported beneficial ownership of 7,205,939 shares, representing 5.08% of Natera Inc.'s common stock, as of March 31, 2026.

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a 7.8% beneficial ownership stake in Natera Inc. as of December 31, 2025.

JPMorgan Chase & Co. has disclosed a 9.1% beneficial ownership stake in Natera, Inc., holding over 12.8 million shares as of December 31, 2025.

T. Rowe Price Associates, Inc. has reported an 8.9% beneficial ownership stake in Natera Inc., holding over 12.19 million shares of common stock.

JPMorgan Chase & Co. has reported a 7.7% beneficial ownership stake in Natera, Inc., held passively for investment purposes.

T. Rowe Price Associates, Inc. has reported a 7.8% beneficial ownership stake in Natera Inc., holding over 10.5 million shares as of March 31, 2025.